SCN2B

Across TCGA pan-cancer cohorts, SCN2B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SCN2B data layer compared with 24 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SCN2B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SCN2B expression acts as an unfavorable survival marker.

STAD, LUSC, and SKCM are the cancer types where SCN2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.149	0.710	<.001	15	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	12	view →
SKCM	DFS	Median	II,III,IV	0.015	0.709	<.001	11	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SCN2B–STAD (DFS)

Open the STAD breakdown →